“This case reinforces the role of tissue culture when histology fails to demonstrate a diagnosis and emphasizes the need for efficient communication between the pediatrician, otolaryngologist, and pathologist for timely excision,” the authors write.
The researchers found that the median progression-free survival was 6.7 and 4.0 months for patients treated with TTFields/TMZ and TMZ alone, respectively.
Cannabidiol could be beneficial for the treatment of oral mucositis, although data on its use in dentistry are scarce, according to a review published online February 12 in the Journal of Clinical Pharmacy and Therapeutics.
The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.
For patients with laryngeal squamous cell carcinoma (SCC), factors predictive of recurrence include neck metastasis at presentation and nonsurgical treatment, according to a study published online November 30 in Head & Neck.
This slideshow reviews drug information for OPDIVO (nivolumab). Click here for the complete OPDIVO product monograph. For a downloadable PDF of this slideshow, click here.
An updated index incorporating gene and molecular alterations can predict survival in non-small-cell lung cancer (NSCLC) with brain metastases.
The Food and Drug Administration (FDA) has approved a new indication for Opdivo (nivolumab injection; Bristol-Myers Squibb).
For patients taking antiretroviral medications, HIV continues to reside in tissues, and though this may not cause AIDS, it could contribute to the development of unrelated conditions such as cancer and cardiovascular disease, according to research published in the October issue of the Journal of Virology.
A radiomic-based approach can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior to bevacizumab treatment, according to a study published online in Clinical Cancer Research.
